provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
Jakafi Coupon - Jakafi 10mg tablet

Jakafi

ruxolitinib
Used for Myelofibrosis, Polycythemia Vera
Used for Myelofibrosis, Polycythemia Vera

Jakafi (ruxolitinib) is a JAK inhibitor that’s used to treat adults with certain blood conditions called myelofibrosis (MF) and polycythemia vera (PV). This medication is also used to treat graft-versus-host disease (GVHD) in people 12 years and older. Jakafi (ruxolitinib) is a tablet that you take by mouth twice a day. It can cause side effects like low blood cell counts, infection, and tiredness.

Last reviewed on June 20, 2024
basics-icon

What is Jakafi (ruxolitinib)?

What is Jakafi (ruxolitinib) used for?

How Jakafi (ruxolitinib) works

Jakafi (ruxolitinib) is a JAK inhibitor. It works by blocking the activity of JAK proteins in the body.

In myelofibrosis and polycythemia vera, JAK proteins send signals that tell your blood cells to grow and divide too quickly. When Jakafi (ruxolitinib) blocks JAK, blood cells can’t grow out of control as well.

And in graft-versus-host disease, JAK proteins play a role in turning on the immune system and damaging tissues. By blocking JAK, Jakafi (ruxolitinib) helps prevent the immune system from becoming too active.

Are you looking for information on Opzelura (ruxolitinib) cream instead?

Drug Facts

Common BrandsJakafi
Drug ClassJAK inhibitor
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
basics-icon

What are the side effects of Jakafi (ruxolitinib)?

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

Other Side Effects

  • Nausea
  • Dizziness
  • Headache
  • Tiredness
  • Trouble breathing
  • Bleeding or bruising
  • High blood pressure
Note: Side effects reported from clinical studies differed depending on what condition people were taking Jakafi (ruxolitinib) for.

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following.
  • Low white blood cells and infection: fever, chills, severe tiredness, body aches, cough, trouble breathing
  • Low platelets and bleeding: unexplained bruising, nosebleeds, blood in urine, blood in stool
  • Serious heart problems: chest pain, chest tightness, trouble breathing, passing out
  • Stroke: numbness or weakness on one side of the body; sudden headache; trouble breathing, speaking, or walking
  • Blood clot: swelling in one arm or one leg, sudden and severe chest pain, trouble breathing

Source: DailyMed

The following side effects have also been reported

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

More common

Black, tarry stools

bladder pain

bleeding gums

blood in the urine or stools

blurred vision

bruising

chills

cloudy urine

collection of blood under the skin

cough

coughing up blood

deep, dark purple bruise

difficult, burning, or painful urination

difficulty in breathing or swallowing

dizziness

fever

frequent urge to urinate

headache

hoarseness

increased menstrual flow or vaginal bleeding

itching, pain, redness, or swelling

large, flat, blue or purplish patches in the skin

lower back or side pain

nervousness

nosebleeds

painful or difficult urination

pale skin

paralysis

pinpoint red spots on the skin

pounding in the ears

prolonged bleeding from cuts

pus in the urine

red or dark brown urine

small, red or purple spots on the skin

slow or fast heartbeat

sore throat

swelling

tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area

tightness in the chest

troubled breathing with exertion

ulcers, sores, or white spots in the mouth

unusual bleeding or bruising

unusual tiredness or weakness

Less common

Painful blisters on the trunk of the body

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Bloated or full feeling

diarrhea

excess air or gas in the stomach or bowels

feeling of constant movement of self or surroundings

passing gas

sensation of spinning

skin rash

weight gain

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

pros-and-cons

Pros and cons of Jakafi (ruxolitinib)

thumbs-up

Pros

Taken by mouth; no needles required

Recommended treatment for myelofibrosis and polycythemia vera

Doesn’t typically cause nausea or vomiting

Works in a more targeted, specific way than traditional chemotherapy

thumbs-down

Cons

Taken twice a day and might require dose changes often

Often causes low blood cell counts

Might raise your risk for infection

pharmacist-tips

Pharmacist tips for Jakafi (ruxolitinib)

pharmacist
  • You can take Jakafi (ruxolitinib) with or without food.

    • If you miss your Jakafi (ruxolitinib) dose, don’t take an extra dose of medication. Just wait until the next scheduled time to take Jakafi (ruxolitinib) at your usual dose.

      • Unless your oncologist or hematologist recommends it, you shouldn’t suddenly stop taking Jakafi (ruxolitinib). Otherwise, your symptoms might come back. Your prescriber will typically slowly lower your dose until you can completely stop the medication.

        • Your treatment plan with Jakafi (ruxolitinib) might need to change depending on your blood counts. Make sure you go to your lab appointments so your care team can check your blood counts and adjust your dose as needed.

          • Give your oncology or hematology care team an up-to-date list of medications that you take. Update your list if you start any new medications or stop taking any. Certain drug interactions with Jakafi (ruxolitinib) can put you at risk for side effects from the cancer medication, while others can make the cancer medication work less well. Your care team can check that your medications are safe to take together.

            • You shouldn’t breastfeed while you’re taking Jakafi (ruxolitinib) and for 2 weeks after your last dose. We don’t know whether Jakafi (ruxolitinib) passes into human milk, but there’s a possible risk of harm to a nursing infant.

              faqs

              Frequently asked questions about Jakafi (ruxolitinib)

              Is Jakafi (ruxolitinib) chemotherapy?
              No, Jakafi (ruxolitinib) isn’t considered chemotherapy. Traditional chemotherapy works by destroying cells that grow quickly, which can include cancer cells, blood cells, and hair cells. Jakafi (ruxolitinib) is a type of targeted therapy that works by blocking a specific protein called JAK. The JAK protein sends signals in the body that tell these cells to grow. So when Jakafi (ruxolitinib) blocks JAK, this growth signal gets interrupted. This helps manage certain conditions where the body makes too many blood and immune cells.
              How long can you take Jakafi (ruxolitinib)?
              You should take Jakafi (ruxolitinib) as recommended by your oncologist or hematologist. Typically, your care team will check how well the medication is working for you after 6 months of treatment. Then, they’ll decide whether you should keep taking it or not. It’s important that you don’t suddenly stop taking Jakafi (ruxolitinib) unless your care team instructs you to. Some people who stopped taking Jakafi (ruxolitinib) too quickly had serious problems, like fever, trouble breathing, low blood pressure, a serious blood-clotting problem, or organ failure. Your prescriber will typically slowly lower your dose before you can completely stop taking the medication to help prevent these symptoms.
              What are the most common side effects of Jakafi (ruxolitinib)?
              The most common side effect of Jakafi (ruxolitinib) is having low blood cell counts. The red blood cell levels in your body might drop, which can lead to anemia; this can make you feel more tired. In addition, having low white blood cells can put you at risk for getting sick since white blood cells normally help fight infection. And having a low platelet count means that you’re at risk for bleeding because your blood might not be able to clot well. Your care team will check your blood counts often while you’re taking Jakafi (ruxolitinib). Contact your care team if you have a fever, if you feel very tired, or if you have any unusual bruising or bleeding. These can be signs of having low blood cell counts.
              Is Jakafi (ruxolitinib) an immunosuppressant?
              Some people might consider Jakafi (ruxolitinib) as an immunosuppressant because the medication can weaken your immune system and put you at risk for serious infections. Jakafi (ruxolitinib) can make your white blood cell levels drop, which lowers your body’s ability to protect you from infection. Don’t start taking Jakafi (ruxolitinib) if you currently have a serious infection. Your oncologist or hematologist might prescribe certain medications, such as antibiotics or antivirals, to help prevent new infections during treatment. Contact your care team right away if you have any signs or symptoms of an infection, like fever, cough, trouble breathing, muscle aches, chills, or severe tiredness.
              How long does Jakafi (ruxolitinib) stay in your system?
              It takes about 15 hours for Jakafi (ruxolitinib) to leave your system after you take a single dose. This time frame is estimated from the medication’s half-life, the time it takes for the levels of the medication to drop by half in the body. Your kidneys and liver help get rid of Jakafi (ruxolitinib) from the body. So the medication might stay in your system longer if you have kidney or liver problems. You’ll probably take a lower dose of Jakafi (ruxolitinib) if you have kidney or liver problems to prevent the medication from building up in the body and lower the risk for side effects.
              Can Jakafi (ruxolitinib) be cut in half or split?
              The manufacturer doesn’t say whether the Jakafi (ruxolitinib) tablets can be cut in half or split. To be safe, swallow the tablets whole. Let your oncologist or hematologist know if you have trouble swallowing tablets whole or if you have a feeding tube called a nasogastric (NG) tube. Your prescriber can discuss with you about your options.
              Can you drink alcohol while you’re taking Jakafi (ruxolitinib)?
              It’s best to avoid drinking alcohol while you’re taking Jakafi (ruxolitinib). Regularly drinking alcohol can make your treatment work less well. In addition, alcohol can raise your risk for liver damage and make it harder for you to recover from infections, both of which are already risks that come with taking Jakafi (ruxolitinib). What’s more, long-term alcohol use can put you at risk for other cancers. Speak with your prescriber about your drinking habits. They can refer you to resources to help you cope or stop drinking, if needed.
              Can I take Jakafi (ruxolitinib) if I have high cholesterol?
              Talk to your oncologist or hematologist before you start taking Jakafi (ruxolitinib) if you have high cholesterol or high triglyceride levels. Jakafi (ruxolitinib) can make your cholesterol and triglyceride levels go up. To keep an eye on your cholesterol levels during treatment, your prescriber will check your blood work every 2 to 3 months while you’re taking Jakafi (ruxolitinib). Typically, medications like statins can help manage high cholesterol levels.
              GoodRxEducationalIcon

              How to save using GoodRx

              Compare Prices
              1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
              Select your free coupon
              2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
              Show coupon to your pharmacist
              3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
              Get free couponLearn more
              warings-icon

              What are the risks and warnings for Jakafi (ruxolitinib)?

              Jakafi (ruxolitinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

              risk-warning

              Low blood cell counts

              People who take Jakafi (ruxolitinib) can have a low blood cell count. This means that the number of red and white blood cells and platelets you have in your blood can drop. When your red blood cells are low, you might feel more tired. And because white blood cells help your body fight infection, you’re at risk for infection when you don’t have enough white blood cells to protect you. In addition, when your platelets are low, your body can’t stop bleeding as well.

              You’ll need to get blood work every so often during treatment so your care team can check your blood count. If your blood count is too low, your oncologist or hematologist might recommend that you take a break from Jakafi (ruxolitinib) or take a lower dose of the medication until your blood count gets back up. If necessary, you might need a blood transfusion of red blood cells or platelets.

              risk-warning

              Risk of infection

              • Risk factors: Travel to countries with high occurrence of tuberculosis | History of tuberculosis | History of herpes simplex infection

                People who take Jakafi (ruxolitinib) have a higher risk of infection, including bacterial, fungal, and viral infections. Some infections that can develop during treatment, such as tuberculosis (TB), can be serious.

                Before you start treatment, let your care team know about any infections you currently have or have had in the past. You shouldn’t start Jakafi (ruxolitinib) if you currently have a serious infection. Depending on what medical condition you’re taking Jakafi (ruxolitinib) for and your history of infections, you might need to take certain medications, such as an antibiotic or antiviral, to help prevent new infections.

                Contact your care team right away if you have signs or symptoms of an infection, such as fever, cough, trouble breathing, muscle aches, chills, or severe tiredness.

                risk-warning

                Risks when Jakafi (ruxolitinib) is paused or stopped

                • Risk factors: Taking Jakafi (ruxolitinib) for myelofibrosis (MF) or polycythemia vera (PV)

                  Sometimes, people who stopped taking Jakafi (ruxolitinib) for myelofibrosis or polycythemia vera developed symptoms similar to those they had before treatment started. Some people also had fever, trouble breathing, low blood pressure, a blood-clotting condition called disseminated intravascular coagulation (DIC), or even organ failure.

                  Because of these risks, it’s important that you don’t suddenly stop taking Jakafi (ruxolitinib) without first talking with your oncologist or hematologist. Typically, your prescriber will slowly lower the dose (instead of suddenly stopping the medication). This helps prevent symptoms of your condition from coming back or other complications.

                  risk-warning

                  Skin cancer

                  Some people developed a new skin cancer after they started taking Jakafi (ruxolitinib). Types of skin cancers that were reported included basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma. Make sure to regularly check your skin and contact your oncologist or a dermatologist if you notice any unusual changes.

                  risk-warning

                  Possible risk for serious heart problems and stroke

                  • Risk factors: Having risk factors for heart problems | Current or past smoker

                    People with rheumatoid arthritis who took a different JAK inhibitor than Jakafi (ruxolitinib) have had serious heart problems, such as heart attack, and stroke. Some of these problems were life-threatening. Jakafi (ruxolitinib) isn’t approved for use in rheumatoid arthritis.

                    Since JAK inhibitors like Jakafi (ruxolitinib) work similarly to each other, your oncologist or hematologist will discuss the possible risk for serious heart problems and stroke with you. They’ll consider the risks and benefits for you to take Jakafi (ruxolitinib). Call 911 right away if you have sudden chest pain; numbness on one side of the body; trouble breathing, speaking, or walking; or sudden nausea and sweating.

                    risk-warning

                    Possible risk for blood clots

                    People with rheumatoid arthritis who took a different JAK inhibitor than Jakafi (ruxolitinib) have developed blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), during treatment. Jakafi (ruxolitinib) isn’t approved for use in rheumatoid arthritis.

                    Since JAK inhibitors like Jakafi (ruxolitinib) work similarly to each other, you should watch for symptoms of blood clots during treatment. Seek medical help right away if you have symptoms of a blood clot, such as swelling in one arm or one leg, sudden chest pain, and sudden trouble breathing.

                    risk-warning

                    Possible risk for new cancers

                    • Risk factors: New cancer that’s developed | Current or past smoker

                      People with rheumatoid arthritis who took a different JAK inhibitor than Jakafi (ruxolitinib) have a higher risk of developing new cancers, such as lymphoma. This risk appears to be even higher for people who smoke or have smoked in the past. Talk with your oncology or hematology care team if you’re concerned about the risk of developing a new cancer with Jakafi (ruxolitinib).

                      dosage

                      Jakafi (ruxolitinib) dosage forms

                      Typical dosing for Jakafi (ruxolitinib)

                      • Myelofibrosis: The typical starting dose is either 5 mg, 15 mg, or 20 mg by mouth twice a day. It’ll depend on your platelet levels at the start of treatment. Your prescriber might adjust the dose during treatment based on your blood counts and your condition.

                      • Polycythemia vera: The typical starting dose is 10 mg by mouth twice a day. Your prescriber might adjust the dose during treatment based on your blood counts and your condition.

                      • Acute graft-versus-host disease: The typical starting dose is 5 mg by mouth twice a day for at least 3 days. Your prescriber might raise the dose to 10 mg twice a day depending on your blood counts.

                      • Chronic graft-versus-host disease: The typical starting dose is 10 mg by mouth twice a day.

                      Your prescriber might recommend a lower starting dose if you have liver or kidney problems. Your starting dose might also be lower if you’re taking certain medications that can interact with Jakafi (ruxolitinib).

                      During treatment, your dose might be lowered if you have concerning side effects.

                      interactions

                      Interactions between Jakafi (ruxolitinib) and other drugs

                      Jakafi (ruxolitinib) may interact with certain medications or supplements. Always let your doctor and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking. The list below does not include all possible drug interactions with Jakafi (ruxolitinib). Please note that only the generic name of each medication is listed below.

                      Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

                      latest news

                      What is the latest news about Jakafi (ruxolitinib)?

                      images

                      Jakafi (ruxolitinib) images

                      White Round Incy And 10 - Jakafi 10mg Tablet
                      This medicine is White, Round Tablet Imprinted With "Incy" And "10".White Round Incy And 10 - Jakafi 10mg Tablet

                      Get savings updates for Jakafi (ruxolitinib)

                      Receive price alerts, news, and other messages from GoodRx about Jakafi (ruxolitinib) and other healthcare topics and relevant savings offers.

                      By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

                      References

                      Best studies we found
                      View All References (20)

                      American Cancer Society. (2024). Anemia (low red blood cell counts).

                      American Cancer Society. (2024). Neutropenia (low white blood cell counts).

                      American Cancer Society. (2024). Thrombocytopenia (low platelet count).

                      American Red Cross. (n.d.). Blood transfusion process.

                      Arana Yi, C., et al. (2015). Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncology.

                      Centers for Disease Control and Prevention. (n.d.). What you need to know: Neutropenia and risk for infection.

                      Incyte Corporation. (2023). Jakafi- ruxolitinib tablet [package insert]. DailyMed.

                      Jacobsohn, D. A., et al. (2007). Acute graft versus host disease. Orphanet Journal of Rare Diseases.

                      Leukemia & Lymphoma Society. (n.d.). Graft-versus-host disease.

                      Leukemia & Lymphoma Society. (n.d.). Lymphoma.

                      Leukemia & Lymphoma Society. (n.d.). Myelofibrosis.

                      Leukemia & Lymphoma Society. (n.d.). Polycythemia vera.

                      Lussana, F., et al. (2017). Ruxolitinib associated infections: A systematic review and meta-analysis. American Journal of Hematology.

                      MedlinePlus. (2023). Platelet count.

                      National Cancer Institute. (n.d.). Myelosuppression.

                      National Comprehensive Cancer Network. (2024). Myeloproliferative neoplasms.

                      National Heart, Lung, and Blood Institute. (2022). Disseminated intravascular coagulation (DIC).

                      Phillips, C. (2023). Drinking alcohol, often heavily, common among people with cancer and long-term survivors. National Cancer Institute.

                      Sabaawy, H. E., et al. (2021). JAK/STAT of all trades: Linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis.

                      Skin Cancer Foundation. (2024). Merkel cell carcinoma overview.

                      GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
                      Was this page helpful?

                      Browse medications

                      View All

                      Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.